Johnson & Johnson - Product Pipeline Review - 2014

Published: Mar, 2014 | Pages: 268 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Johnson & Johnson - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Johnson & Johnson - Product Pipeline Review - 2014', provides an overview of the Johnson & Johnson's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Johnson & Johnson's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Johnson & Johnson including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Johnson & Johnson's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Johnson & Johnson's pipeline products

Reasons to buy

- Evaluate Johnson & Johnson's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Johnson & Johnson in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Johnson & Johnson's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Johnson & Johnson and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Johnson & Johnson
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Johnson & Johnson and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Johnson & Johnson Snapshot 7
Johnson & Johnson Overview 7
Key Information 7
Key Facts 7
Johnson & Johnson - Research and Development Overview 8
Key Therapeutic Areas 8
Johnson & Johnson - Pipeline Review 15
Pipeline Products by Stage of Development 15
Pipeline Products - Monotherapy 16
Pipeline Products - Combination Treatment Modalities 17
Pipeline Products - Partnered Products 18
Pipeline Products - Out-Licensed Products 22
Johnson & Johnson - Pipeline Products Glance 24
Johnson & Johnson - Late Stage Pipeline Products 24
Johnson & Johnson - Clinical Stage Pipeline Products 28
Johnson & Johnson - Early Stage Pipeline Products 32
Johnson & Johnson - Unknown Stage Pipeline Products 36
Johnson & Johnson - Drug Profiles 37
(canagliflozin + metformin) IR 37
abiraterone acetate 39
bedaquiline fumarate 42
canagliflozin 44
golimumab 46
paliperidone palmitate ER 49
siltuximab 50
simeprevir 54
bortezomib 59
(canagliflozin + metformin) XR 64
(sumatriptan succinate + naproxen sodium) 65
ARN-509 67
infliximab 69
sirukumab 71
tapentadol hydrochloride 73
tapentadol hydrochloride ER 74
trabectedin 77
ustekinumab 80
CNTO-3157 82
CNTO-6785 83
esketamine 84
fulranumab 86
guselkumab 88
JNJ-37822681 90
JNJ-38518168 92
JNJ-40346527 94
JNJ-40411813 95
JNJ-40929837 96
JNJ-54452840 97
JNJ-54781532 99
quisinostat 100
RV-568 102
TMC-310911 104
TMC-353121 105
TMC-647055 106
EVT-100 Series 108
EVT-103 109
telaprevir 110
CNTO-0007 113
intetumumab 114
JNJ-26528398 116
JNJ-38877618 117
JNJ-39269646 118
JNJ-42165279 119
JNJ-42396302 120
JNJ-42692507 121
JNJ-42721458 122
JNJ-42756493 123
JNJ-42847922 125
JNJ-47910382 126
JNJ-53773187 127
JNJ-54861911 128
Retroviral Transduced T-Cell Therapy For HIV 129
rilpivirine 130
RV-1162 132
RV-1729 133
tipifarnib 134
Adenoviral Vector Based Human ABCG1 Gene Therapy 136
Arylamide FMS Inhibitors For Rheumatoid Arthritis 137
Autoimmune Disease Program 138
CNTO-530 139
Drugs For Diabetes 140
FLT3 Inhibitors For AML 141
JNJ-26070109 142
JNJ-26993135 143
JNJ-28312141 144
JNJ-28610244 145
JNJ-31020028 146
JNJ-35815208 147
JNJ-39220675 148
JNJ-39933673 149
JNJ-40413269 150
JNJ-47965567 151
JNJ-5234801 152
JNJ-7777120 153
mAb-1A11 154
mAb-5G7 155
Pam2Cys 156
RV-1088 157
S-961 158
serdemetan 159
Small Molecule To Inhibit Endothelial Lipase For Hypercholesterolemia 161
Stem Cell Therapy for Diabetes 162
Tricyclic aminopyrimidine 163
Dendritic Cell-Based Vaccine 164
Diarylquinolines 165
Drugs for Cancer 166
ESN-JJ 167
Hepatitis B Program 168
JNJ-39729209 169
Peptides for Chronic Pain 170
SARD Program 171
Small Molecule for Smoking Cessation 172
Small Molecules To Inhibit FGFR For Cancer 173
Program For Influenza 174
Johnson & Johnson - Pipeline Analysis 175
Johnson & Johnson - Pipeline Products by Target 175
Johnson & Johnson - Pipeline Products by Route of Administration 180
Johnson & Johnson - Pipeline Products by Molecule Type 182
Johnson & Johnson - Pipeline Products by Mechanism of Action 184
Johnson & Johnson - Recent Pipeline Updates 189
Johnson & Johnson - Dormant Projects 238
Johnson & Johnson - Discontinued Pipeline Products 245
Discontinued Pipeline Product Profiles 245
Johnson & Johnson - Locations And Subsidiaries 247
Head Office 247
Other Locations & Subsidiaries 247
Appendix 261
Methodology 261
Coverage 261
Secondary Research 261
Primary Research 261
Expert Panel Validation 261
Contact Us 262
Disclaimer 262

List of Tables
Johnson & Johnson, Key Information 13
Johnson & Johnson, Key Facts 13
Johnson & Johnson - Pipeline by Indication, 2014 15
Johnson & Johnson - Pipeline by Stage of Development, 2014 21
Johnson & Johnson - Monotherapy Products in Pipeline, 2014 22
Johnson & Johnson - Combination Treatment Modalities in Pipeline, 2014 23
Johnson & Johnson - Partnered Products in Pipeline, 2014 24
Johnson & Johnson - Partnered Products/ Combination Treatment Modalities, 2014 25
Johnson & Johnson - Out-Licensed Products in Pipeline, 2014 28
Johnson & Johnson - Out-Licensed Products/ Combination Treatment Modalities, 2014 29
Johnson & Johnson - Pre-Registration, 2014 30
Johnson & Johnson - Filing rejected/Withdrawn, 2014 31
Johnson & Johnson - Phase III, 2014 32
Johnson & Johnson - Phase II, 2014 34
Johnson & Johnson - Phase I, 2014 36
Johnson & Johnson - Preclinical, 2014 38
Johnson & Johnson - Discovery, 2014 41
Johnson & Johnson - Unknown, 2014 42
Johnson & Johnson - Pipeline by Target, 2014 182
Johnson & Johnson - Pipeline by Route of Administration, 2014 187
Johnson & Johnson - Pipeline by Molecule Type, 2014 189
Johnson & Johnson - Pipeline Products by Mechanism of Action, 2014 191
Johnson & Johnson - Recent Pipeline Updates, 2014 195
Johnson & Johnson - Dormant Developmental Projects,2014 244
Johnson & Johnson - Discontinued Pipeline Products, 2014 251
Johnson & Johnson, Subsidiaries 253